HIV-Associated Neuroretinal Disorder in Patients With Well-Suppressed HIV-Infection: A Comparative Cohort Study
Authors:
- Nazli DemirkayaNDNazli Demirkaya
- Michael D. AbramoffMAMichael D. Abramoff
- on behalf of the AGEhIV Cohort Study GroupOGon behalf of the AGEhIV Cohort Study Group
Open Access
- 1 March 2016
- journal article
- clinical trial
- Published by Association for Research in Vision and Ophthalmology (ARVO) in Investigative Ophthalmology & Visual Science
- Vol. 57 (3) , 1388-1397
Abstract
Purpose: Loss of neuroretinal structure and function, ascribed to a ‘HIV-associated Neuroretinal Disorder' (HIV-NRD), in the absence of ocular opportunistic infections, has been reported in HIV-infected individuals treated with combination antiretroviral therapy (cART). Whether HIV-infected individuals with prolonged well-suppressed infection remain at risk for HIV-NRD, is unknown. Methods: Ninety-two HIV-infected men with suppressed viremia on cART for at least 12 months (HIV+) and 63 HIV-uninfected, highly comparable, male controls (HIV−), aged at least 45 years, underwent functional measurements of spatial (Pelli Robson contrast sensitivity [PR CS]) and temporal contrast sensitivity (TCS) and straylight, as well as spectral-domain optical coherence tomography analysis measured total and individual retinal layer thickness. Mixed-linear regression models were used to assess possible associations between HIV-related and ocular parameters, while accounting for several confounders. Results: Pelli Robson CS was significantly lower in HIV+ (1.89 vs. 1.93 logCS, P value = 0.001), while TCS values did not differ (2.17 vs. 2.17 logCS; P value = 0.888). Straylight values were higher in HIV+ (1.15 vs. 1.09 log units; P value = 0.026). Peripheral total retinal thickness in the HIV+ group was increased compared with HIV− (+4.6 μm, P value = 0.029), predominantly due to an increase in inner nuclear layer (+1.04 μm, P value = 0.006) and outer plexiform layer (+0.95 μm, P value = 0.006) thickness. Conclusions: Pelli Robson CS was significantly reduced in HIV-infected individuals, although the loss was one letter and likely not clinically relevant. Instead of an expected neuroretinal thinning, an increase of retinal thickness was detected in the HIV-infected group. These findings should be confirmed and further explored in longitudinal studies. Clinical Trial registered at www.clinicaltrials.gov (identifier: NCT01466582).Keywords
This publication has 43 references indexed in Scilit:
- Faculty Opinions recommendation of Central and peripheral markers of neurodegeneration and monocyte activation in HIV-associated neurocognitive disorders.2017
- Central and peripheral markers of neurodegeneration and monocyte activation in HIV-associated neurocognitive disordersJournal of NeuroVirology, 2015
- Retinal Vessel Caliber Among People With Acquired Immunodeficiency Syndrome: Relationships With Visual FunctionAmerican Journal of Ophthalmology, 2012
- Structural and Functional Assessment in HIV-Infected Patients Using Optical Coherence Tomography and Frequency-Doubling Technology PerimetryAmerican Journal of Ophthalmology, 2010
- Vision Function in HIV-Infected Individuals without Retinitis: Report of the Studies of Ocular Complications of AIDS Research GroupAmerican Journal of Ophthalmology, 2008
- Contrast Sensitivity and Color Vision in HIV-infected Individuals Without Infectious RetinopathyAmerican Journal of Ophthalmology, 2006
- Mechanisms of Neuroimmunity and Neurodegeneration Associated with HIV-1 Infection and AIDSJournal of Neuroimmune Pharmacology, 2006
- Objective analysis of retinal damage in HIV-positive patients in the HAART era using OCTAmerican Journal of Ophthalmology, 2005
- Simple non-invasive assessment of advanced glycation endproduct accumulationDiabetologia, 2004
- Distance and Near Visual Acuity, Contrast Sensitivity, and Visual Fields of 10-Year-Old ChildrenArchives of Ophthalmology (1950), 1999